Please type a plus sign (+) inside this box [+]

PTO/SB/05 (1998)
Approved for use through 9/30/00, OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No,	960296.95491
First Inventor or Application Identifier	William F. Dove
Title	METHOD FOR IDENTIFYING MUTANTS AND MOLECULES
Express Mail Label No.	EE450090526US

APPLICATION ELEMENTS
See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: **Assistant Commissioner for Patents**
Box Patent Application
Washington, D.C. 20231

1 [X] Fee transmittal Form
(Submit an original and a duplicate for fee processing)

2 [X] Specification [Total 33]
(preferred arrangement set forth below)
- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed Sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3 [X] Drawing(s) (35 USC 113) [Total Sheets 1]

4. Oath or Declaration [Total Pages 3]
a. [X] Newly executed (original or copy)
b. [ ] Copy from prior Application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)
[Note Box 5 below]
i. [ ] DELETION OF INVENTOR(S) Signed Statement attached deleting inventor(s) named in prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

5 [ ] Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference herein.

6. [ ] Microfiche Computer Program *(Appendix)*

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
[ ] Computer readable Copy
[ ] Paper Copy (identical to computer copy)
[ ] Statement Verifying identity of above

ACCOMPANYING APPLICATION PARTS

8 [ ] Assignment Papers (cover sheet & documents)
9 [ ] 37 CFR 3.73(b) Statement (where there is an assignee) [ ] Power of Attorney
10 [ ] English Translation Document *(if applicable)*
11 [ ] Information Disclosure Statement (IDS)/PTO-1449 [ ] Copies of IDS Citations
12 [ ] Preliminary Amendment
13 [X] Return receipt postcard (MPEP 503) *(Should be specifically itemized)*
14 [ ] *Small Entity Statement(s) [ ] Statement filed in prior application Status still proper and desired
15 [ ] Certified copy of priority Document(s) *(if foreign priority is claimed)*
16 [ ] Other:
* A new statement is required to pay small entity fees, except where one has been filed in a prior application and is being relied upon

17. If a CONTINUING APPLICATION, *check appropriate box and supply the requisite information:*
[ ] Continuation [ ] Divisional [X] Continuation-in-part (CIP) of prior application no. 08/751,292
Prior application information: Examiner: S. Zitomer Group/Art Unit: 1807

18. CORRESPONDENCE ADDRESS

[ ] Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label) or [X] Correspondence address below

NAME	Bennett J. Berson Quarles & Brady				
ADDRESS	P O Box 2113				
CITY	Madison	STATE	WI	ZIP CODE	53701-2113
COUNTRY	US	TELEPHONE	608/251-5000	FAX	608/251-9166

Name (Print/Type)	Bennett J. Berson	Registration No. (Attorney/Agent)	37,094
Signature		Date	July 14, 1998

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. QBMAD\165636

Firstar Plaza
P.O. Box 2113
Madison, Wisconsin 53701-2113
608/251-5000
FAX 608/251-9166
http://www.quarles.com

Attorneys at Law in
Milwaukee and Madison, Wisconsin
West Palm Beach and Naples, Florida
Phoenix, Arizona

Quarles & Brady

July 14, 1998

Assistant Commissioner of Patents
Box Patent Application
Washington DC 20231

Re: Filing New Patent Application

Dear Sir:

Enclosed for filing please find a new patent application entitled: METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

by William F. Dove
Alexandra Shedlovsky

The undersigned hereby certifies that this document is being deposited with the United States Postal Service today, July 14, 1998, by the "Express Mail" service, utilizing Express Mail label number EE450090526US, addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Please indicate receipt of this application by returning the attached postcard with the official Patent and Trademark Office receipt and serial number stamped thereon.

Respectfully submitted,

QBMAD\165635
Enclosures

EXPRESS MAIL LABEL NO. EE450090526US

PTO/SB/17 (1/98)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.
Small Entity payments must be supported by a small entity statement otherwise large entity fees must be paid, See Forms PTO/SB/09-12

TOTAL AMOUNT OF PAYMENT	$ 655.00

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	William F. Dove
Group Art Unit	
Examiner Name	
Attorney Docket Number	960296.95491

METHOD OF PAYMENT (check one)

1. [X] The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number: 17-0055

Deposit Account Name: Quarles & Brady

[X] Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 [ ] Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)

2. [ ] Payment Enclosed: [ ] Check [ ] Money Order [ ] Other

FEE CALCULATION (fees effective 10/01/97)

1. FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
101	790	201	395	Utility filing fee	395.00
106	330	206	165	Design filing fee	
107	540	207	270	Plant filing fee	
108	790	208	395	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) ($)395.00

2. CLAIMS

		Extra		Fee from below		Fee Paid
Total Claims	25	-20**=	5	X 11	=	55.00
Independent Claims	8	-3**=	5	X 41	=	205.00
Multiple Dependent Claims					=	

** or number previously paid, if greater, For reissues see below

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
103	22	203	11	Claims in excess of 20
102	82	202	41	Independent cla ms in excess of 3
104	270	204	135	Multiple dependent claim
109	80	209	40	**Reissue independent claims over original patent
110	22	210	11	**Reissue claims in excess of 20 and over origina patent

SUBTOTAL (2) ($)260.00

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)		Fee
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	*920	112	*920	Requesting publication of SIR prior to Examiner action	
113	*1,840	113	*1,840	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	950	217	475	Extension for reply within third month	
118	1,510	218	755	Extension for reply within fourth month	
128	2,060	228	1,030	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive unavoidably abandoned application	
141	1,320	241	660	Petition to revive unintentionally abandoned application	
142	1,320	242	660	Utility issue fee (or reissue)	
143	450	243	225	Design issue fee	
144	670	244	335	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))	
149	790	249	395	For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify) _____

Other fee (specify) _____

SUBTOTAL (3) ($)

* Reduced by Basic Filing Fee Paid

SUBMITTED BY				Complete (if applicable)	
Typed or Printed Name	Bennett J. Berson			Reg. Number	37,094
Signature		Date	July 14, 1998	Deposit Account User ID	

QBMAD\165639

METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application serial number 08/751,292 filed November 18, 1996, incorporated herein in its entirety by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.

BACKGROUND OF THE INVENTION

Worldwide efforts to determine the genomic DNA sequences of humans and other animals are ongoing. Such efforts typically focus on obtaining sequence information from cDNAs in libraries created from RNAs of various tissues. Thus, collections of "expressed sequence tags" (ESTs) include portions of coding regions from most human genes.

Although ESTs provide useful structural information, they offer little insight into the functional relationship among genes. The functional relationship is of particular importance to determining the set of genes involved in a biological process and, subsequently, to developing pharmaceutical agents that affect one or more of the components of the biological process. See, e.g., Friedrich, G. A., "Moving Beyond the Genome Projects: Does the Future of Genomics-Based Drug Discovery Lie With the Mouse?," Nature Biotechnology 14:1234-1237 (1996).

Friedrich argues in favor of using model systems that mirror human physiology in determining which genes may be involved in a biological process, and suggests that the mouse is an excellent model organism for human biology in that it shares with humans most salient aspects of mammalian physiology. The genomes of mice and humans are approximately the same in size, organization, and structure. Friedrich

proposes that the mouse can be developed as an effective tool for drug development. Friedrich puts forth a "radical" suggestion that there is no logical barrier hindering large-scale phenotypic screens using mice.

Friedrich proposes using an insertional mutagen in embryonic stem cells to generate random mutations in the mouse genome, then screening for a variety of pre-determined phenotypes and cloning affected genes.

In particular, the physiology of, and treatments for, colon cancer are of particular biomedical interest. Colon cancer is one of the most prevalent malignancies in the Western world, with an estimated 145,000 new cases and 60,000 deaths each year in the United States alone. Genetic factors play a key role in this disease. Mutations in the human adenomatous polyposis coli (*APC*) gene cause a set of familial colon cancer syndromes. Mice carrying a mutation in a corresponding gene (*Apc*) also develop many intestinal adenomas. Heterozygotes for the *Min* (*M*ultiple *I*ntestinal *N*eoplasia) allele of the mouse *Apc* gene develop numerous intestinal and colonic adenomas [on average 29 Å 10, on a C57BL/6J (or equivalent derivative) background] that are similar in morphology to the adenomas seen in human inherited colonic polyposis syndromes such as familial adenomatous polyposis and Gardner's syndrome. *Min/Min* homozygotes die *in utero*. The *Min* mutation maps to mouse chromosome 18. The sequence of the *Apc* gene is known and published. *Min* mice carry a nonsense mutation in exon 15 of the mouse *Apc* gene (a mutation of the sort typically seen in human colon cancer kindreds). Mice carrying *Min* thus provide a model system for studying human familial adenomatous polyposis.

A locus (*Mom*-1) that strongly modifies the tumor number in heterozygous *Min*/+ mice was mapped to distal chromosome 4. Dietrich, W.F., et al., "Genetic Identification of *Mom-1*, a major modifier locus affecting *Min*-induced intestinal neoplasia in the mouse," Cell 75:631-639 (1993). *Mom-1* lies in a region of synteny conservation with human chromosome 1p35-36, a region of frequent somatic loss of heterozygosity in a variety of human tumors, including colon tumors. *Mom-1* is only one of an

unknown number of loci that modify the expression of an inherited cancer syndrome, and it does not explain all of the genetic variation in tumor number in intraspecific backcrosses.

What is lacking is a systematic method for pinpointing genetic loci involved in modifying known phenotypes, by enhancing or suppressing. In the particular case of colon cancer in humans and animals, it would be desirable to locate the sequences in the genome (and the molecules encoded by those sequences) that are involved in the appearance of intestinal adenomas. The lack of such a systematic method has limited understanding of oncogenesis and, as such, has precluded development of pharmaceuticals that modify the oncogenic process. A systematic method should include not only non-essential loci, for which numerous mutant alleles can be found among homozygous inbred mouse strains, but also essential loci, for which mutant alleles in heterozygous form may influence the phenotype. Mutations that inactivate an essential gene will normally be lethal when homozygous, and so will not be found among inbred mouse strains.

BRIEF SUMMARY OF THE INVENTION

The present invention permits detection of a genetic locus or loci that can modify a chosen known phenotype conferred by a chosen dominant allele. The method includes a mutagenic process that facilitates identifying and isolating the genetic sequences that encode the molecules that can modify the chosen phenotype, as well as the phenotype-modifying molecules themselves.

The method can be practiced using inbred strains of non-human animals, which are preferably mammals, and more preferably rodents. Inbred strains of mice, rats and rabbits are available. In the present method, mice are the non-human mammalian animals of choice, because of the synteny between humans and mice and because the genetics and breeding of mice are highly developed. Further, the mouse can exhibit disease phenotypes that are very similar to those of humans, as in the exemplified embodiment. The murine genetic sequences and the

molecules obtained in the method are used to secure corresponding sequences and molecules from humans. The human sequences and molecules are then employed in known methods to develop pharmaceutical agents.

The basic breeding method includes the following steps. Each of a set of mice of a founder inbred mouse strain is mutagenized and then bred to the same inbred strain to produce an inbred holding generation ("Generation 1" or "Gen1"). The animals of the Gen1 founder mouse strain carry random point mutations relative to wild-type mice of that strain. Gen1 mice are outcrossed with a mouse of an index inbred mouse strain to obtain Gen1F_1 progeny. The index inbred mouse strain carries a dominant allele at a locus known to confer a chosen phenotype. The chosen phenotype is designated the "index phenotype." The index phenotype, which focuses the screening method on the phenotype of interest, is characterized in an index strain and provides a reference phenotype against which possible mutants can be compared. The dominant index allele can include any condition that brings a biological process into a range in which it responds to heterozygous enhancer or suppressor mutations of the sort identified in the present invention. The condition can be a cognizable genetic condition or might even be a non-genetic environmental condition. At least some of the Gen1 F_1 progeny carry both the dominant allele and at least one random mutation that may modify the index phenotype conferred by the dominant allele. A founder animal is judged to be of interest if a subset of its Gen1F_1 progeny are extensively modified for the index phenotype.

When a founder mouse has at least one Gen1F_1 offspring that displays a modified phenotype relative to control animals, the founder (Gen1) animal is crossed to an unmutagenized mouse of the founder strain to produce second generation (Gen2) offspring. Those offspring are again outcrossed to the index strain to obtain Gen2F_1 progeny. The presence of a phenotype-modifying mutation is then verified if a subset of the Gen2F_1 progeny are also modified for the index phenotype. Again, a cluster of animals with modified index phenotypes gives

increasing confidence that the Gen1 founder carries a mutation of interest.

Genetic material that comprises the phenotype-modifying mutation can then be obtained using methods known to the art. Molecules encoded by the genetic material may also be obtained. The obtained genetic materials and molecules (or corresponding human equivalents) are used in methods known to the art to produce pharmaceutical agents that can ameliorate phenotypes noted in human or non-human patients affected in the biological process of interest.

It is an object of the present invention to provide a rapid, focused approach to obtaining genes in a model mammalian organism that can affect a biomedically-relevant phenotype.

It is an advantage of the present invention that the method can simultaneously identify an ensemble of several genes that can modify the index phenotype.

It is another advantage of the present invention that the method can uncover genes having no other known phenotype.

The present invention offers advantages over existing methods of obtaining genes, such as analysis of ESTs, in that genes secured in the present method are necessarily relevant to a biological phenotype. In contrast, genome-sequencing methods can provide voluminous sequence information for many genes, but offer little or no guidance as to the functional relationship among sequenced genes.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Fig. 1 depicts the probability of survival of Gen1F_1 mice bred in accordance with the method of the present invention. Fig. 1 also depicts the survival times of individuals of four kindreds that exhibited progeny with longer or shorter survival times relative to the average survival time of Gen1F_1 mice carrying the index *Min* allele. Longer-surviving suppressor (Su) candidate kindreds 248 and 258 are shown as squares. Shorter-surviving enhancer (En) candidate kindreds 333 and 425 are shown as circles.

DETAILED DESCRIPTION OF THE INVENTION

A goal of the present invention is to identify genetic loci and genetic sequences that can modify a known phenotype. Although such analysis employing mutagenesis cannot be performed in humans for ethical reasons, the synteny and sequence conservation between human and mouse genomes provides a facile bridge to identify such loci and sequences in the human. It is likely that such sequences will correlate with existing human genetic sequence information. Thus, equivalent loci and genetic sequences can be sought in the human genome using conventional, available hybridization and PCR techniques.

The method is an Index-directed, Cluster-enhanced, Modifier locus and Molecule identification method that can be referred to as an "ICMM method."

The availability of inbred mice having a well defined genetic composition and well-studied phenotypes that model human syndromes, diseases, and other conditions, makes the mouse the preferred mammalian species in which to practice the present method. A preferred mouse species is *Mus musculus*.

The breeding system described herein is premised upon the existence of a phenotype that is evident in mice heterozygous for the allele that confers the chosen index phenotype. It is always preferable to employ an index strain that carries an allele that gives the index phenotype in the heterozygous state. The index phenotype can be made "evident" by visual, biochemical, or other detection means. The phenotype-controlling allele can be lethal when present in the homozygous state. For cancer, the phenotype can relate either to effects that follow from the presence of an activated cancer-inducing allele or else from inactivation of a tumor suppressor gene that causes tumor formation in the absence of one normal copy of the gene. The phenotype can be governed by an allele on a sex chromosome or on an autosome. If the allele is on a sex chromosome, the breedings described herein are modified in a manner known to the art to ensure that the allele is maintained in the breeding pool.

The index phenotype is preferably conferred by a single

dominant allele, although by taking care to produce suitable founder animals, phenotypes under the control of more than one locus can be studied in the method. It is not necessary that the phenotype-conferring allele is a defined genetic sequence, but rather the allele can be defined by classical genetic methods. It is advantageous that the allele is tightly linked to a genetic marker for genotype analysis, as is described elsewhere herein. With the dense microsatellite map of the mouse genome currently available, this condition is always met.

Phenotype-modifying loci are obtained in the present invention. A "modification" is any demonstrable change in an index phenotype relative to control animals lacking the phenotype-modifying allele, including, without limitation, enhancing or suppressing a phenotype, such as prolonging or shortening an animal's life span or circadian behavior. It is not necessary that the whole animal be affected by the modification. For example, a modified phenotype may be a change in a particular behavior or a change in the level of a particular biomolecule, such as a blood protein, after introducing a phenotype-modifying mutant allele in the method of the present invention. The assay for modified outliers in the first stage of the screen, Gen1F_1, will usually be relatively crude. One must judge whether an outlier is in the first or last 10 percentile range of the phenotypic distribution. For example, in a strain of mice having a well-defined running activity governed by a single dominant mutation (*Clock*)," the method described herein can be used to obtain animals having modified timing of that running activity. The genetic material (and protein molecules) responsible for that modification can be obtained by mapping and positionally cloning the modifying mutation.

The system is particularly amenable to study of genetic interactions in cancers known to have a genetic component. In particular, humans that carry an aberrant *APC* gene are predisposed to develop numerous tumors in the intestinal tract. Mice heterozygous for the *Min* allele of *Apc*, the murine homolog of human *APC*, also develop numerous tumors in the intestinal

tract, similar to human inherited colonic polyposis syndromes. It is demonstrated herein that mutations induced in the genome elsewhere than at the *Apc* locus can modify the survival rate and intestinal tumor load of mice carrying the *Min* allele at that locus.

Several important breeding considerations direct the selection of inbred mouse strains for use in the method. It is understood that those skilled in the art of mouse breeding are familiar with the breeding requirements of available mouse strains and such requirements need not be restated here.

The strain into which random mutations are introduced must be an inbred strain so that all modifications are the result of induced mutagenesis rather than genomic divergence. The strain should be susceptible to efficient germline mutagenesis. By "susceptible" the applicants intend that the strain have characteristic forward mutation rates of at least 1/500 per gamete per locus. In addition, the strain should have a long breeding span of at least one year. Also, it is preferred that the strain yield large litters, on average 8 or more pups per litter. A strain meeting these requirements is the inbred strain BTBR, which is available from the Jackson Laboratory, Bar Harbor, Maine.

It is important that the inbred strain in which mutations are induced can be distinguished from the strain that contains the phenotype-conferring allele, e.g., by restriction fragment length polymorphisms (RFLP) or by simple sequence length polymorphisms (SSLP). A high incidence of informative differences in standard genetic markers between the two strains is important for mapping and cloning any mutation of interest. In one embodiment of the invention, the index phenotype (*Min*) was provided on a background of C57BL/6J (or equivalent derivative) (hereinafter, "B6-*Min*"). An "equivalent derivative" has an index phenotype comparable to that of B6-*Min* on a genuine C57BL/6J background. The BTBR strain used for mutagenesis in this embodiment is polymorphic at approximately half of the SSLP marker loci, relative to the B6 inbred strain In heterozygous form, BTBR has no strong effect on the *Min*

phenotype.

It is also important that the two strains used in the method be relatively free of polymorphic dominant modifiers of the chosen index phenotype. By "relatively free" the applicants intend that differences in the index phenotype between Gen1F_1 animals and the index strain be sufficiently minor so as not to mask the effects of newly induced mutations. One skilled in the art will be able to determine the permissible variation for any given index phenotype. For example, in the case of the *Min* index phenotype, Gen1F_1 animals should show no more than about a 1.5-fold change in tumor multiplicity compared to B6-*Min*. In the *Clock* case, there should be no more than a 30 minute shift in circadian rhythm.

In the method, the strain that is to be mutagenized is treated with a mutagenic agent that induces mutations in the germline. It is important, for reasons associated with subsequent detection and isolation of mutants of interest, that the mutagen be an efficient point mutagen that can induce at least one mutation per locus per 500 gametes in the founder animal strain. Ethylnitrosourea (ENU) is a suitable and preferred mutagen which introduces almost exclusively point mutations in the mouse germline. A suitable protocol for ENU mutagenesis of mice is described in Shedlovsky et al., Genet. Res., Camb. 47:135-142 (1986), incorporated herein by reference. It is preferred, but not essential, that the mutagenesis be performed on male mice, since it is possible to obtain many offspring from a single mutagenized male. The mice are then crossed with unmutagenized mice of the same strain to produce isogenic animals, heterozygous only for the various mutations induced by the mutagenesis.

Each member of the set of Gen1 animals is crossed to mice heterozygous for the mutation conferring the index phenotype. It is desirable to produce up to 1000 of such Gen1 animals, to maximize the statistical likelihood that each of the approximately $1x10^5$ genes in the mouse genome is examined at least once. If the mutation frequency is 1 per locus per 500 gametes, a 1000-member library of Gen1 animals would contain an

average of 2 hits for each locus that can modify the index phenotype. The probability that a salient locus would escape attention would then be e^{-2} or ë10%. The cross can be done using Gen1 animals of either gender, unless the index phenotype compromises the successful breeding of one gender. It is sometimes possible to foster offspring when the female parent is compromised.

The kindreds are evaluated as follows. The phenotypic behaviors of the full set of Gen1F_1 animals are scored as are the phenotypes of individual kindreds. Where no modification is present, the behavior of individuals in the kindred would range over the average behavior of the full set. However, if a modifying mutation has been induced, and since the founder parent was heterozygous for the modifying mutation, on average 50% of the members of the kindred will show an outlying phenotype.

To improve the statistical likelihood that a modified phenotype is genuine, it is preferred that the modification be observed in two or more animals of a kindred having four or more members. A further condensation of the method is possible under these conditions. See, *infra*. It is most preferred that the kindred have at least six members and that three or more members are affected. It may be fruitful, however, to study smaller kindreds containing a single extreme outlier.

The female parents of kindreds that evidence possible modification by the above-noted standard are then crossed to unmutagenized mice of the same founder strain to maintain the mutation on a fixed background (a "copying generation"). The offspring of the copying generation are crossed again to mice heterozygous for the chosen phenotype to assess whether any of their offspring carry a *bona fide* modifying mutation. A genotypic analysis can be performed to determine which of these offspring carry the gene that confers the index phenotype. It can be particularly important to characterize the offspring quickly if the phenotype is one that affects the lifespan of the Gen1 founder animals.

Mice shown by genotypic analysis to carry the index

determinant are assessed as early as possible to determine whether any modification is apparent. If such a modified phenotype is observed, the specific genetic sequences responsible for the modification can be systematically identified using technology now available to the art. See, e.g., Zhang, Y. et al, "Positional cloning of the mouse *obese* gene and its human homologue," Nature 372:425-432 (1994); Kusumi, K. et al., "The mouse pudgy mutation disrupts *Delta* homologue *D113* and initiation of early somite boundaries," Nature Genetics, 19:274 (1998); and King, D. P., et al., "Positional Cloning in the Mouse Circadian *Clock* Gene, "Cell 89:641 (1997), all incorporated herein by reference in their entirety. Each gives a concrete example of mutation-guided positional cloning. In the latter example, mutations were induced with ENU. In this approach, murine coding sequences are identified on a contig (a contiguous nucleic sequence of a portion of a chromosome determined by analyzing of a set of overlapping component nucleic acid sequences) constructed in the region of markers linked to a mutation. The murine coding sequences were identified by exon trapping (Church, D. M., et al, Nature Genet. 6:98-105 (1994), incorporated herein by reference), sequencing of trapped exons, comparing the sequences of trapped exons to all sequences in Genbank, screening putative exons for the presence of corresponding RNA in a variety of tissues by northern blots and reverse-transcription PCR. Then, by known methods of hybridization to human genetic material, the corresponding human gene was obtained. Alternatively, PCR primers prepared from the murine genetic sequences can be used to amplify corresponding human sequences from human genetic material. One skilled in the art can readily determine the similarity required between murine-derived primers and human target sequences in PCR methods.

While the method described above is effective for finding segregating mutations that modify an index phenotype, the method is improved by providing a first improved method that more rapidly identifies modifiers having a severe and

pronounced heterozygous enhancing or suppressing impact on an index phenotype, or by providing a second improved method that facilitates identifying and mapping modifiers by reducing genetic background noise. The improved methods are described below.

It is also noted that male gametes can now be advantageously harvested at sexual maturity (approximately 6 weeks for mice) and preserved indefinitely or used in an *in vitro* fertilization method, for example, according to the published method of Sztein, J.M., J.S. Farley J.S., A.F. Young and L.E. Mobraaten, "Motility of cryopreserved mouse spermatozoa affected by temperature of collection and rate of thawing," Cryobiology 35 (1):46-52 (1998), incorporated herein by reference in its entirety. By using the cryopreservation method, germplasm found to comprise a modifying mutation can be rescued and used in any cross described herein, even if the source animal is, at the time, too old or too ill to breed. Each male yields sufficient sperm to produce at least 500 progeny. In each cross described, it is also preferred that animals (or, more broadly, gametes) that potentially contribute a modifier into the cross be male animals (or gametes), unless a maternal effect is involved in the index phenotype, because so many more gametes can be screened using males rather than females. Depending upon the strains used, foster mothering may be required.

The first improved method, which is more compact and more efficient than the prior method, requires fewer crossing steps, eliminates a holding generation, and can be useful where the modified index phenotype accelerates death or reduces breeding capacity. This improved method sacrifices some of the strength of the 2-generation dominant modifier screen in that it does not present a candidate on the basis of a cluster of outliers on the survival curve and in that it loses strict isogenicity after the first generation. However, it does aim efficiently at modifiers in vital genes whose cloning can be pursued as described. In this improved method, one can detect new modifier alleles, both for extreme enhancer and suppressor

outliers in the F_1 generation, or instead can use the cluster principle of the basic method to confirm subtle F_1 outliers by screening for clusters of animals more subtly modified in the backcross (N2) generation. An "extreme" outlying phenotype can be defined on a case-by-case basis, depending upon the nature of the index phenotype. A non-limiting example would be a phenotype enhanced or suppressed to a level below the tenth percentile or above the ninetieth percentile, respectively. In another case, for example, "extreme" levels might be established at the second and ninety-eighth percentiles. A "subtle" change is a change that is within statistical noise in the F_1 animals, but first becomes statistically significant in the backcross generation or subsequent cross.

In the first improved method, a mutagenized inbred animal of an appropriate strain is mated directly to an animal of the index strain to produce F_1 progeny that are screen for modified index phenotype.

If an F_1 animal appears to carry a modifier mutation, it is backcrossed to the index strain (with or without the index allele) to yield N2 progeny. At this generation, multiple animals are screened to find clusters of progeny with a modified phenotype. Clusters of animals that exhibit the modified phenotype carry the modifier mutation, while those that do not exhibit the modification fail to carry the mutation. Carriers must be heterozygous for alleles genetically linked to the locus, while non-carriers must be homozygous for the index strain at those same loci. Thus, these animals provide the material for mapping the new mutation using well-known PCR-based mapping methods (SSLPs and SNPs). Single nucleotide polymorphisms are described in Kruglyak, L. "The Use of a Genetic Map of Biallelic Markers in Linkage Studies," Nature Genetics 17:21 (1997), incorporated herein by reference in its entirety.

The second improved method facilitates identifying and mapping of modifying mutations by reducing genetic background noise. The method is an isogenic modifier screening method in which animals that contribute the dominant allele and the

founder inbred animals that carry random point mutations share an inbred genetic background. Apart from the dominant index allele, the index animals are closely matched to the mutation-carrying founder inbred animals.

Two embodiments of this second improved method are contemplated. In the first embodiment, enhancer and suppressor modifiers can both be detected when the genetic background shared by the index animals and the founder animals has no apparent effect on the index phenotype. In an example of this embodiment, an index mouse strain can contain a *Min* allele at an Apc locus on a C57BL/6J (B6) background while the mutagenized founder animals can be B6 mice.

In the second embodiment of this method, the genetic background affects the index phenotype, in that when the dominant allele that confers the index phenotype is provided on a particular genetic background, the index phenotype is enhanced or suppressed in the animal, facilitating selective detection of suppressing or enhancing modifiers, respectively. The index strain can be a congenic derivative of a strain that has a genetic background that enhances or suppresses the index phenotype, wherein the congenic strain carries the dominant allele that confers an index phenotype. For example, in a congenic strain having a *Min* allele at an *Apc* locus, on the genetic background of the inbred BTBR strain, the *Min* phenotype is significantly enhanced.

Congenic inbred animals carrying the index allele are crossed to animals that have been mutagenized as described elsewhere herein to produce Gen1 animals. Suppression and/or enhancement of the index phenotype can be assessed as described. Where the index parent in this cross has an enhanced index phenotype, putative suppressing modifiers of the index phenotype can be apparent in some Gen1 animals as a shift in the index phenotype away from the enhanced level and toward the wild-type level. Putative modifiers in Gen1 animals can be mapped by crossing the Gen1 animals to a genetically distinguishable inbred strain.

In each instance, to facilitate mapping and cloning of a

putative modifier, animals that contain a putative modifier are crossed to genetically distinguishable germplasm because mapping methods demand differences between the animals that contain putative modifiers and strains used for mapping. However, polymorphic differences in the genetic backgrounds of these strains can obscure the phenotype modification exerted by an induced enhancer or suppressor mutation. This problem can be overcome by creating an index strain that differs from the founder strain only at single nucleotide polymorphisms (SNPs) peppered about its genome. Briefly, an isogenic index strain is created by mutagenizing the index strain using a mutagen that induces single nucleotide changes, such as ENU. The SNP-marked index strain is created by systematic brother-sister mating, starting with a son and a daughter of the mutagenized animal who had been mated to the animal carrying the index mutation. The process of sequential brother-sister sib-mating gradually eliminates detrimental and lethal mutations. To validate that the introduced SNP markers are phenotypically neutral, the index phenotype of the SNP-marked strain can be assessed. By way of example, ENU mutagenesis of BTBR or B6 mouse strains can be expected to produce such marker polymorphisms at a density in the range of 1 per centiMorgan. The approach of preparing such an index strain permits genetic screens to be as close to isogenic as one can envision.

The methods for identifying heterozygous carriers of enhancers and suppressors of an index phenotype can be effectively guided by applying an appropriate statistical analysis to the phenotypic data in candidate kindreds (e.g., tumor count, in the case of *Min*). Using the algorithm, it is possible to enhance the efficiency with which one identifies likely carriers and noncarriers of a candidate heterozygous modifier gene.

The first part of a suitable two-part statistical analysis, confirms the presence of a modifier gene segregating in a candidate kindred by applying a likelihood ratio test of the null hypothesis that no phenotype-modifying gene is segregating. The likelihood ratio test considers the

alternative hypothesis that one modifier gene is segregating, and the test is calibrated exactly by Monte Carlo; that is, a p-value is obtained by calculating the likelihood ratio statistic repeatedly for random permutations of animals among subkindreds. For a discrete phenotype such as tumor count, background and modified phenotype distributions are modeled as negative binomials. Gaussian distributions may be appropriate for continuous phenotypes. If the p-value > 0.05, there is no evidence for a modifier gene. Either more data are needed, or different kindreds should be considered for further analysis.

If the p-value < 0.05, then, in the second part of the analysis, a LOD score for the presence of the modifier gene is calculated for each potential carrier that has offspring with phenotype information. The LOD score is the base 10 logarithm of the ratio of the probability of offspring phenotype data if the animal carries the modifier gene compared to the probability of the phenotype data if the animal does not carry the modifier gene. Probabilities are calculated from an estimated background distribution for the denominator, and from a mixture of the estimated background and estimated modified distribution for the numerator. Estimated distributions are obtained by the method of maximum likelihood. Negative binomial distributions can be used for tumor count phenotype, and Gaussian distributions can be used for continuous phenotypes. Potential carriers are then ranked according to their LOD scores. Mapping proceeds by first analyzing animals with highest positive LOD scores (likely carriers) and highest negative LOD scores (likely noncarriers).

An ENU-induced modifier mutation can be mapped to low resolution on the basis of their heterozygous phenotype, as outlined above. As detailed near the end of the Example below, higher resolution mapping is available when homozygotes for the ENU-induced modifier mutation have a qualitatively distinct phenotype such as lethality.

The invention will be better understood upon consideration of the following non-limiting Example.

Example

The *Min* mutation, described by Moser et al., "A Dominant Mutation that Predisposes to Multiple Intestinal Neoplasia in the Mouse," Science 247:322-324 (1990), incorporated herein by reference, is a dominantly transmitted, fully penetrant mouse mutation that causes a phenotype in heterozygotes that closely resembles human inherited colonic polyposis syndromes. In this example, C57BL/6 mice carrying the *Min* allele were bred with genetically-distinguishable BTBR mice that carried random point mutations inherited from mutagenized fathers.

At approximately 1 month intervals, 6 to 12 male BTBR mice were treated with ENU according to the protocol described by Shedlovsky, *supra*, and were then crossed to female, unmutagenized BTBR mice. The Gen1 offspring of that cross were isogenic BTBR animals heterozygous for possible mutations that could affect the tumor load in mice that contain the *Min* mutation. Approximately 900 female Gen1 offspring were obtained over time.

Two hundred ninety-five Gen1 female mice were crossed with B6-*Min* male mice. As an aside, it is noted that multiple Gen1 males could have been crossed with B6-*Min* females, if the litters had been raised by foster mothers (such as ICR mice, commercially available) within a few days of birth. Over 90% of such pups survive. This strategy would be advantageous in that by providing multiple B6-*Min* females, production of a sufficient number of Gen1F_1 animals would be accelerated.

To perform the cross, two females and one male were placed in a cage. After two weeks, the females were withdrawn and replaced by two new females. Pregnancies were detected by weekly palpation of separated females. If no pregnancy was detected after two weeks of separation, the female was recycled into matings. The Gen1F_1 progeny from each female were genotyped for *Min* and were screened for signs of illness twice weekly starting at 100 days of age. When the animals began to look pale they were screened daily until they appeared close to death. The genotypic analysis employed allele-specific PCR or allele-specific hybridization, as described by Dietrich et al.,

supra, at page 637, and papers cited therein, all incorporated herein by reference, using the same PCR primers and conditions used by Dietrich et al.

Among the progeny were 92 kindreds having 6 or more members. Of these 92 kindreds, 5 kindreds showed at least two *Min*/+ members with possible enhancement of the *Min* phenotype (that is, a survival time shorter than the 90th percentile survival of the total population of Gen1F_1 mice). Seven kindreds showed at least two *Min*/+ members with suppression of the *Min* phenotype (that is, longer survival than the 10th percentile). As expected, the enhancement or suppression of the phenotype segregated within a kindred, since the *Min* mice in the Gen1F_1 generation of a kindred are heterozygous for any newly-induced mutations.

The following table shows survival of four kindreds that include segregating candidate enhancer or suppressor loci:

Kindred Number	Mouse Number	Born	Died	Last Age	% survival on Gen1F_1 curve
Su248	1	10/20/yr1	11/11/yr2	388	2.9
	3	10/20/yr1	08/21/yr2	306	5.3
	2	10/20/yr1	07/26/yr2	280	6.6
	6	10/20/yr1	04/12/yr2	175	32.1
Su258	4	10/11/yr1	11/12/yr2	398	0.0
	2	10/11/yr1	10/16/yr2	371	3.4
	14	02/14/yr2	09/30/yr2	229	11.0
	6	12/13/yr1	07/01/yr2	201	17.0
	7	12/13/yr1	06/19/yr2	189	22.4
	3	10/11/yr1	04/16/yr2	188	22.6
	11	12/13/yr1	05/25/yr2	164	43.3
En333	15	03/06/yr2	08/05/yr2	152	56.1
	3	10/25/yr1	03/14/yr2	141	70.8
	12	03/06/yr2	07/23/yr2	139	72.7
	2	10/25/yr1	03/12/yr2	139	72.7
	13	03/06/yr2	06/18/yr2	104	98.7
	11	03/06/yr2	06/18/yr2	104	98.7
	10	03/06/yr2	06/18/yr2	104	98.7
	17	03/06/yr2	06/18/yr2	104	98.7
En425	3	11/10/yr1	04/05/yr2	147	62.7
	1	11/10/yr1	03/25/yr2	136	76.4
	2	11/10/yr1	03/12/yr2	123	89.5
	6	11/10/yr1	03/12/yr2	123	89.5
	8	11/10/yr1	02/27/yr2	109	97.3
	6	11/10/yr1	02/27/yr2	109	97.3

If the probability is 10% that a mouse of normal genotype will survive longer than a particular age, the random probability that 2 mice in the same kindred will survive longer than that age is only 1%. The random probability that 3 mice in a kindred will survive longer is only 0.1%, in turn. Therefore, as the number of members of a kindred having an outlying short or long survival increases, so does the likelihood that the deviation results from a *bona fide* mutation inherited from the mutagenized BTBR founder animal. This is the cluster principle of the method. By predetermining a desired level of clustering, one can set limits on the ability to detect mutants and can raise the purification level of mutants obtained, thereby enriching the screen for mutants.

Fig. 1 depicts the probability of survival versus age in the Gen1F_1 generation of the cross between Gen1 BTBR females and B6-*Min* males. The symbols below and to the left of the curve reflect individuals in 2 kindreds thought to contain mutations that enhance the *Min* phenotype (En333 and En425). The symbols above and to the right of the curve reflect the members of 2 kindreds for whom the *Min* phenotype appears to be suppressed (Su248 and Su258). A number of the mice in the latter category remained alive at more than 365 days of age. Mice that showed statistically lower or higher survival were bred using standard methods to maintain the mutation. In some cases, the Gen1 animal failed to breed and the long term surviving Gen1F_1 mice were bred to the wild-type founder strain instead, as a fallback method for rescuing mutations of interest. For example, the founder parent of kindred Su258, described *infra*, was not able breed after a candidate mutation was identified in her progeny. Long-lived progeny animals number 2 and 4 were, therefore, bred to BTBR mice.

To verify that these outlying members of a kindred do indeed contain an enhancing or suppressing mutation, a second-generation kindred was examined. This is useful both to recover carriers of a strong enhancer mutation and to detect more subtle dominant affects of either the suppressor or the enhancer class. Commonly, heterozygotes for a loss of gene

function show only a subtle heterozygous effect.

To produce the second generation kindred, the founder animal that gave rise to a kindred that evidenced either an enhancing or suppressing function was crossed to normal BTBR animals. On average, 50% of the offspring of this cross would be expected to contain the suppressing or enhancing mutation. The offspring of this cross, termed Gen2, were crossed to B6-*Min* mice.

After 90 days, the progeny shown by genotypic analysis to carry the *Min* mutation were sacrificed and tumor load was assessed using standard methods for determining average tumor volume and number. Tumor load is defined as average tumor volume times the number of tumors per mouse.

As further proof that a suppressing mutation was obtained in kindred 258, two of the long-term survivors in the Gen1F_1 generation were bred and descendants were found to have very low tumor counts (about 10 or fewer tumors). This provided strong evidence that a bona fide mutation having the effect of suppressing the *Min* phenotype was segregating upon passage to the offspring. On the basis of 699 animals in suppressor kindred 258, the statistically estimated tumor multiplicity of +/+ animals is 18.8, on average, while that of the Su/+ animals is estimated as 5.9. For enhancer kindred 333, the estimated tumor multiplicity of the +/+ animals is 20.5 while the En/+ members of the kindred have an estimated tumor multiplicity of 36.

Because of the known SSLP polymorphisms between B6 and BTBR DNA, it will be possible to isolate the portion of the progeny genome that contains BTBR DNA and thereafter to localize the point mutation responsible for modifying the phenotype using standard techniques now available to the skilled molecular geneticist. The fact that ENU-induced mutations are single basepair substitutions makes this step particularly powerful. This is the basis for the "Modifying Molecule" appellation of the ICMM method. The portion of the genome containing the point mutation can be compared against known ESTs, or can be sequenced *de novo* to determine the

genetic sequence responsible for encoding the molecule that modifies the phenotype. Using standard methods, the genetic sequence can be introduced into a suitable genetic construct containing a transcriptional promoter for production in a prokaryotic or eukaryotic host cell. One could use the cloned gene to produce other mutations in this gene in companion mouse strains.

The genetic sequence is readily compared against known sequences from humans to determine the identity of the corresponding human gene. The human gene can be isolated by standard methods of hybridization, PCR, or expression cloning. The human protein can likewise be obtained using standard techniques, either by isolation from human tissue, or by production in a non-native host using recombinant DNA methods.

It may be possible to isolate mutations that suppress the index *Min* phenotype in a more compact, albeit less sensitive, method. In this method, B6-*Min* (heterozygous) female mice are crossed directly with ENU-mutagenized BTBR male mice. As a control, non-mutagenized BTBR male mice are also processed in the same way. The F_1 offspring are fostered on ICR mice. Male F_1 mice that have the *Min* phenotype are maintained.

At 170 days, any $Apc^{Min/+}$ F_1 male whose body weight is greater than 95% of the control body weight is considered a candidate carrier of a dominant suppressor of the *Min* phenotype, *Su*/+.

Such candidate carriers are bred at 170 days of age to wild-type B6 female mice. The female offspring of this cross ($Apc^{Min/+}$ and $Apc^{+/+}$) are backcrossed to the candidate male who is by now only about 230 days old.

The progeny of the latter cross are then phenotyped at 90 days of age. By this time, the candidate male is at least 340 days old. Among the progeny, any detrimental or lethal phenotypes will inform about the map position of the suppressor and will indicate whether the candidate male carries a suppressor mutation.

Apc$^{Min/+}$ Progeny:

+/+	normal *Min* phenotype
Su/+	low tumor load at 90 days?
Su/*Su*	very low tumor load at 90 days? or detrimental or lethal?

Apc$^{+/+}$ Progeny:

+/+	normal
Su/+	normal?
Su/*Su*	detrimental or lethal?

Detrimentally affected animals will be homozygous for BTBR markers linked to the suppressor locus. By contrast, if *Su*/*Su* is an embryonic lethal mutation, the set of liveborn progeny will lack animals homozygous for BTBR markers linked to the suppressor locus.

It may also be important to rescue germplasm carrying a modifier mutation that enhances or suppresses, but particularly those that enhance, the *Min* phenotype, using *in vitro* fertilization. For example, a candidate carrier male who might be too sick to breed can be sacrificed. Sperm taken from the sacrificed male can be used to fertilize eggs obtained from a suitable female (e.g., BTBR or a mouse that carries the mutation of interest). The techniques that can be employed are described in Hogan, B. et al., Manipulation of the Mouse Embryo, Cold Spring Harbor Laboratory Press, 2nd. ed. (1994), incorporated herein by reference.

It is intended that the foregoing examples are non-limiting on the invention, but rather that the invention encompasses all such modifications and variations as come within the scope of the following claims.

CLAIMS

WE CLAIM:

1. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

outcrossing a founder inbred strain to an index inbred strain to obtain F_1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F_1 progeny that carry the dominant allele also carry at least one random mutation;

backcrossing the F_1 progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype; and

verifying that the outlying phenotype is caused by a segregating mutation.

2. A method as claimed in Claim 1 wherein any of the crosses employ preserved gametes.

3. A method as claimed in Claim 1 wherein the F_1 progeny and some of the N2 progeny exhibit an extreme outlying phenotype.

4. A method as claimed in Claim 3 wherein the segregating mutation is a heterozygous modifier of the index phenotype selected from a group consisting of an enhancing modifier and a suppressing modifier.

5. A method as claimed in Claim 1 wherein the dominant allele is a *Min* allele at an *Apc* locus.

6. A method as claimed in Claim 1 wherein the index inbred strain is an isogenic index strain that carries single nucleotide polymorphisms.

7. A method as claimed in Claim 6 wherein the isogenic index strain is produced by a method comprising the steps of:

treating an animal of an index strain with a mutagenic agent to induce point mutations in the treated animal;

crossing the treated animal to an animal of the index strain to produce F1 progeny; and

sib-mating F1 and subsequent generation progeny until detrimental and lethal mutations are eliminated.

8. A method as claimed in Claim 1 wherein the founder inbred mouse strain is produced by a method comprising the step of treating a wild-type inbred mouse with a mutagenic agent to induce point mutations.

9. A method as claimed in Claim 8 wherein the mutagenic agent is ethylnitrosourea.

10. A method for identifying a human genetic sequence that corresponds to a segregating mutation at a genetic locus in a non-human animal, the segregating mutation causing an outlying phenotype relative to an index phenotype in an index inbred mouse strain, the method comprising the steps of:

outcrossing a founder inbred non-human strain to an index inbred non-human strain to obtain F_1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F_1 progeny that carry the dominant allele also carry at least one random mutation;

backcrossing the F_1 progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype;

verifying that the outlying phenotype is caused by a segregating mutation;

identifying genetic markers linked to the segregating mutation;

identifying a gene on a contig that encodes the segregating mutation; and

recovering human genetic sequences that correspond to the mutation-encoding gene.

11. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

crossing a founder inbred strain with an index inbred strain to obtain Gen1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, the allele being provided on a genetic background of the wild-type founder inbred strain, wherein some of the Gen1 progeny that carry the dominant allele also exhibit a modified index phenotype; and

verifying that Gen1 progeny that carry the dominant allele and exhibit a modified index phenotype carry a segregating mutation.

12. A method as claimed in Claim 11 wherein the genetic background has no modifying effect upon the index phenotype.

13. A method as claimed in Claim 11 wherein the genetic background has a modifying effect upon the index phenotype.

14. A method as claimed in Claim 13 wherein the genetic background has an enhancing effect upon the index phenotype, and wherein the Gen1 animals exhibit a suppressed phenotype relative to the index inbred strain.

15. A method as claimed in Claim 11 further comprising the steps of:

mapping the segregating mutation by crossing Gen1 animals that have the dominant allele and a modified index phenotype to a genetically distinguishable inbred strain; and

evaluating the progeny of the mapping cross.

16. A method as claimed in Claim 15 wherein the genetically distinguishable inbred strain is an inbred strain having the genetic background of the wild-type founder inbred strain and further comprising single nucleotide polymorphisms relative to the wild-type founder inbred strain.

17. A genetically altered mouse having a genetic background characteristic of a first inbred mouse strain, the mouse comprising in its genome:

a dominant heterozygous allele that confers an index phenotype on a mouse having the characteristic genetic background; and

a segregating modifier of the index phenotype, the modifier being genetically linked to a genetic marker characteristic of a second inbred mouse strain,

wherein the index phenotype in the genetically altered mouse is modified relative to the index phenotype in a mouse that comprises the dominant allele on the genetic background characteristic of the first inbred mouse strain but which lacks the segregating modifier.

18. A mouse as claimed in Claim 17 wherein the dominant allele is a *Min* allele at an Apc locus.

19. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

outcrossing a founder inbred non-human strain to an index inbred non-human strain to obtain F_1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F_1 progeny that carry the dominant allele also carry at least one random mutation;

backcrossing the F_1 progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype;

verifying that the outlying phenotype is caused by a segregating mutation; and

selecting an animal that shows the outlying phenotype.

20. A non-human animal as claimed in Claim 19 wherein the non-human animal is a mouse.

21. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

crossing a founder inbred strain with an index inbred strain to obtain Gen1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, the allele being provided on a genetic background of the wild-type founder inbred strain, wherein some of the Gen1 progeny that carry the dominant allele also exhibit a modified index phenotype;

verifying that Gen1 progeny that carry the dominant allele and exhibit a modified index phenotype carry a segregating mutation; and

selecting an animal that shows the outlying phenotype.

22. A non-human animal as claimed in Claim 21 wherein the non-human animal is a mouse.

23. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

outcrossing a founder isogenic inbred strain with the index inbred strain to obtain Gen1F_1 progeny, the founder isogenic strain being heterozygous only for random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, where at least some of the Gen1F_1 progeny carry both the dominant allele and at least one random mutation;

crossing a founder animal of the founder isogenic inbred strain to an animal of the founder strain that lacks the mutations to obtain inbred Gen2 offspring, where the founder animal has at least one outcrossed F_1 progeny that displays the outlying phenotype relative to the index phenotype;

outcrossing Gen2 offspring to the index strain to obtain Gen2F_1 backcross progeny, half of which, on average, carry the dominant allele that confers the index phenotype; and

verifying that a subset of the Gen2F_1 progeny shows the outlying phenotype; and

selecting an animal that shows the outlying phenotype.

24. A non-human animal as claimed in Claim 23 wherein the non-human animal is a mouse.

25. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

outcrossing a founder isogenic inbred strain with the index inbred strain to obtain Gen1F_1 progeny, the founder isogenic strain being heterozygous only for random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, where at least some of the Gen1F_1 progeny carry both the dominant allele and at least one random mutation;

crossing a founder animal of the founder isogenic inbred strain to an animal of the founder strain that lacks the mutations to obtain inbred Gen2 offspring, where the founder animal has at least one outcrossed F_1 progeny that displays the outlying phenotype relative to the index phenotype;

outcrossing Gen2 offspring to the index strain to obtain Gen2F_1 backcross progeny, half of which, on average, carry the dominant allele that confers the index phenotype; and

verifying that a subset of the Gen2F_1 progeny shows the outlying phenotype.

ABSTRACT OF THE DISCLOSURE

Methods for breeding mutagenized mice permit detection of genetic loci that in heterozygous mutated form can modify a known index phenotype involves crossing a mutagenized founder strain and a second strain of mice carrying an allele at a locus that confers the index phenotype. In the test generation, clusters of individuals are observed to deviate from the typical phenotype. The genetic material and molecules encoded thereby can be obtained using available methods. Improved and compact methods are also disclosed.

SEQUENCE LISTING

Not applicable.

QBMAD\164075

The ICMM Method



FIG 1

PTO/SB/01 (6-95)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box [+]

0010/PTO
Rev 6/95

U.S. Department of Commerce
Patent and Trademark Office

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

[X] Declaration Submitted with Initial Filing OR [ ] Declaration Submitted after Initial Filing

Attorney Docket Number	960296.95491
First Named Inventor	William F. Dove
COMPLETE IF KNOWN	
Application Number	
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am the original, first and so e inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

(Title of the Invention)

the specification of which

[X] is attached hereto

OR

[ ] was filed on (MM/DD/YY) [ ] as United States Application Number or PCT International

Application Number [ ] and was amended on (MM/DD/YY) [ ] (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YY)	Priority Not Claimed	Certified Copy Attached? YES	NO
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]

[ ] Additional foreign applications numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YY)	
		[ ] Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

Burden Hour Statement: This form is estimated to take .4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
QBMAD\165588

Please type a plus sign (+) inside this box [+]

DECLARATION

I hereby claim benefit under Title 35, United States Code §120 of any United States application(s), or §365(C) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT international application in the manner provided in the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YY)	Parent Patent Number *(if applicable)*
08/751,292		11/18/96	

[ ] Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and all continuation and divisional applications based thereon, and to transact all business in the Patent and Trademark Office connected therewith:

[ ] Firm Name _____ Customer Number or label _____

OR

[X] List attorney(s) and/or agent(s) name and registration number below

Name	Registration Number	Name	Registration Number
Thad F. Kryshak	19,428	Gregory A. Nelson	30,577
Neil Hamilton	19,869	Keith M. Baxter	31,233
Thomas W. Ehrmann	20,374	John D. Franzini	31,356
Barry E. Sammons	25,608	Joseph W. Bain	34,290
J. Rodman Steele	25,931	Robert J. Sacco	35,667
Nicholas J. Seay	27,386	Jean C. Baker	35,433
George E. Haas	27,642	David G. Ryser	35,407
Michael J. McGovern	28,326	Bennett J. Berson	37,094
Carl R. Schwartz	29,437	Michael A. Jaskolski	37,551

[ ] Additional attorney(s) and/or agents named on a supplemental priority sheet attached hereto

Please direct all correspondence to [ ] Customer Number or label _____ OR [X] Fill in correspondence address below

Name	Bennett J. Berson
Address	Quarles & Brady
Address	P O Box 2113
City	Madison **State** WI **Zip** 53701-2113
Country	US **Telephone** 608/251-5000 **Fax** 608/251-9166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of Sole or First Inventor: [ ] A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
William	F.	Dove	

Inventor's Signature: William F. Dove. Date: 7.14.98

Residence: City	State	Country	Citizenship
Madison	WI	US	US

Post Office Address: 4130 Mandan Crescent

Post Office Address:

City	State	Zip	Country	Applicant Authority
Madison	WI	53711	US	

[ ] Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box +

DECLARATION	ADDITIONAL INVENTOR(S) Supplemental Sheet

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Alexandra	Middle Initial		Family Name	Shedlovsky	Suffix e.g. Jr.		
Inventor's Signature	Alexandra Shedlovsky					Date	July 14, 1998	
Residence: City	Madison	State	WI	Country	US	Citizenship	US	
Post Office Address	4130 Mandan Crescent							
Post Office Address								
City	Madison	State	WI	Zip	53711	Country	US	Applicant Authority

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name		Middle Initial		Family Name		Suffix e.g. Jr.		
Inventor's Signature						Date		
Residence: City		State		Country		Citizenship		
Post Office Address								
Post Office Address								
City		State		Zip		Country		Applicant Authority

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name		Middle Initial		Family Name		Suffix e.g. Jr.		
Inventor's Signature						Date		
Residence: City		State		Country		Citizenship		
Post Office Address								
Post Office Address								
City		State		Zip		Country		Applicant Authority

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name		Middle Initial		Family Name		Suffix e.g. Jr.		
Inventor's Signature						Date		
Residence: City		State		Country		Citizenship		
Post Office Address								
Post Office Address								
City		State		Zip		Country		Applicant Authority

☐ Additional inventors are being named on supplemental sheet(s) attached hereto